0000950170-24-026492.txt : 20240305
0000950170-24-026492.hdr.sgml : 20240305
20240305182828
ACCESSION NUMBER: 0000950170-24-026492
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khayal Tamer I
CENTRAL INDEX KEY: 0001430462
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38891
FILM NUMBER: 24723163
MAIL ADDRESS:
STREET 1: TRANSMEDICS INC
STREET 2: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TransMedics Group, Inc.
CENTRAL INDEX KEY: 0001756262
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 000000000
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
BUSINESS PHONE: 9785520900
MAIL ADDRESS:
STREET 1: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
4
1
ownership.xml
4
X0508
4
2024-03-01
0001756262
TransMedics Group, Inc.
TMDX
0001430462
Khayal Tamer I
C/O TRANSMEDICS GROUP, INC.
200 MINUTEMAN ROAD
ANDOVER
MA
01810
false
true
false
false
Chief Commercial Officer
true
Common Stock
2024-03-01
4
M
false
10000
13.28
A
36502
D
Common Stock
2024-03-01
4
S
false
2868
81.49
D
33634
D
Common Stock
2024-03-01
4
S
false
1842
82.28
D
31792
D
Common Stock
2024-03-01
4
S
false
3632
83.64
D
28160
D
Common Stock
2024-03-01
4
S
false
424
84.26
D
27736
D
Common Stock
2024-03-01
4
S
false
1234
85.18
D
26502
D
Common Stock
14776
I
By the Khayal Family 2021 Irrevocable Trust
Common Stock
11051
I
By the Tamer Ibrahim Ahmed Khayal Trust
Stock Option (Right to Buy)
13.28
2024-03-01
4
M
false
10000
0.00
D
2032-02-22
Common Stock
10000
32000
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $81.01 to $81.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.01 to $82.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $83.00 to $83.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.035 to $85.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.
By: /s/ Stephen Gordon, Attorney-in-Fact
2024-03-05